Xeljanz Approval History
FDA Approved: Yes (First approved November 6, 2012)
Brand name: Xeljanz
Generic name: tofacitinib
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis
Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis.
Development History and FDA Approval Process for Xeljanz
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.